Structured evidence table for Chromium Body Composition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Body Composition Randomized Trial | Insulin sensitivity improved significantly, with a 28% greater improvement in the active group than in the placebo group (adjusted geometric mean ratio 1.28; 95% confidence interval 1.14 to 1.44). | 2 | Xenos K (2026) | Effects of Berberine, White Mulberry Leaf Extract and Chromium Picolinate on Body Composition and Insulin Resistance in Adults with Obesity: A Randomized Controlled Trial. |
| Chromium Body Composition Randomized Trial | Conclusions The fixed-dose combination improved BIA-derived body-composition measures and OGTT-derived insulin sensitivity over 12 weeks compared with placebo. | 2 | Xenos K (2026) | Effects of Berberine, White Mulberry Leaf Extract and Chromium Picolinate on Body Composition and Insulin Resistance in Adults with Obesity: A Randomized Controlled Trial. |
| Chromium Body Composition Randomized Trial | Objectives To evaluate the efficacy of a fixed-dose combination of berberine, white mulberry leaf extract, and chromium picolinate on body weight, body composition, and insulin sensitivity in Greek adults with obesity. | 2 | Xenos K (2026) | Effects of Berberine, White Mulberry Leaf Extract and Chromium Picolinate on Body Composition and Insulin Resistance in Adults with Obesity: A Randomized Controlled Trial. |
| Chromium Body Composition Randomized Trial | Research methodology/design This was a 12-week, randomized, double-blind, placebo-controlled trial. | 2 | Xenos K (2026) | Effects of Berberine, White Mulberry Leaf Extract and Chromium Picolinate on Body Composition and Insulin Resistance in Adults with Obesity: A Randomized Controlled Trial. |
| Chromium Body Composition Randomized Trial | In patients with PMDD, lower γ-aminobutyric acid (GABAA) receptor δ-subunit expression and higher serotonin binding to the serotonin transporter are found in the luteal phase compared with controls, correlated with altered emotional generation through heightened amygdala activation and worse depressive symptoms, respectively [,]. | 4 | Smith Marleigh (2026) | Self-Reported Changes in Premenstrual and Menstrual Symptoms among Females Taking a Novel Multinutrient Supplement: A Pilot Study |
| Chromium Body Composition Randomized Trial | PMS is found to involve differences in neurotransmitter functioning, inflammation, and oxidative stress, which may contribute to its severity [,,]. | 4 | Smith Marleigh (2026) | Self-Reported Changes in Premenstrual and Menstrual Symptoms among Females Taking a Novel Multinutrient Supplement: A Pilot Study |
| Chromium Body Composition Randomized Trial | Severe menstrual pain is associated with 4-fold higher prostaglandin levels on the first day of menstruation compared with controls []. | 4 | Smith Marleigh (2026) | Self-Reported Changes in Premenstrual and Menstrual Symptoms among Females Taking a Novel Multinutrient Supplement: A Pilot Study |
| Chromium Body Composition Randomized Trial | 1 2 3 4 5 6 4 7 Menstrual cycle symptoms affect ≤90% of menstruating individuals []. | 4 | Smith Marleigh (2026) | Self-Reported Changes in Premenstrual and Menstrual Symptoms among Females Taking a Novel Multinutrient Supplement: A Pilot Study |
Source documents